ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ELUTIA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.82+0.02 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
ELUTIA INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Women's Health | $9.14M | $11.55M | $10.30M | – | – | 74.3% | -20.9% |
| Cardiovascular | $3.16M | $2.91M | $5.04M | – | – | 25.7% | +8.3% |
| Device Protection | – | $9.91M | $9.40M | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Women's Health | – | – | $10.30M | $7.47M | $5.05M | – | – |
| Cardiovascular | – | – | $5.04M | $7.28M | $7.51M | – | – |
| Orthobiologics | – | – | – | $25.34M | $26.93M | – | – |
| Device Protection | – | – | $9.40M | $9.09M | $7.90M | – | – |
By region
From the segment and revenue-disaggregation notes of Elutia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.